INTERIM RESULTS AS OF MARCH 31, 2018
|
|
- Horatio Kennedy
- 5 years ago
- Views:
Transcription
1 INTERIM RESULTS AS OF MARCH 31,
2 FORWARD-LOOKING STATEMENTS This presentation includes forward-looking statements that involve risks, uncertainties and other factors, many of which are outside of our control that could cause actual results to differ materially from the results discussed in the forward-looking statements. Forward-looking statements include statements regarding our short-term objectives and opportunities, financial expectations for the full year and financial preparedness as of year end, as well as statements concerning our plans, objectives, goals, future events, performance and/or other information that is not historical information. All such forward-looking statements are expressly qualified by these cautionary statements and any other cautionary statements which may accompany the forward-looking statements. We undertake no obligation to publicly update or revise forward-looking statements to reflect subsequent events or circumstances after the date made, except as required by law. 2
3 RECENT HIGHLIGHTS IMVAMUNE Strong efficacy data read out from Phase 3; BLA submission expected in H RSV First in class RSV vaccine demonstrated presence of mucosal protective antibodies; booster data and challenge study decision later in 2018 CV301 2 new industry partnerships; 4 Phase 2 studies in combination with ICIs to initiate this year BN-Brachyury Orphan Drug designation obtained from FDA; advancing BN- Brachyury into pivotal registration trial in Chordoma Other business New USG partnership in mosquito-borne illness: Equine Encephalitis 3
4 INVESTING IN THE PIPELINE TO CREATE MORE VALUE Despite a temporary decline in IMVAMUNE revenues, investment in R&D remains a priority. Return to historical revenues anticipated as manufacturing facility is completed. Cash reserves ensure R&D will not be slowed due to resource constraints mdkk E Revenue R&D 4
5 A RE-BALANCED R&D SPEND IN 2018 Revisions to clinical strategy post-prospect represent a more measured approach to oncology investments 2 of 4 CV301 studies now paid for through collaboration with outside investigators and large pharma Clinical design will require evidence of initial efficacy in patients prior to expanding enrollment or investments 10 High Low 0 Market potential current development programs Low Partnered R&D 32% Infectious Disease 42% Cancer 26% Relative risk (scientific & financial) High
6 CV301 MEASURED AND BALANCED CLINICAL STRATEGY During 2018, four Phase 2 trials will evaluate the combination of CV301 and checkpoint inhibitors across three indications Non-small cell lung cancer (NSCLC) Proof-of-concept study of CV301 plus KEYTRUDA (pembrolizumab) as first-line maintenance therapy (n=176) Bladder cancer Phase 2 study of CV301 plus TECENTRIQ (atezolizumab) (n=60) Large, randomized trial which will yield multiple data points 2-stage design: Minimum efficacy thresholds must be met prior to expansion into larger studies Colorectal & Pancreatic cancers Phase 2 study of CV301 plus IMFINZI (durvalumab) and maintenance chemotherapy (n=54) Physician sponsored (Georgetown University) study with financial commitment from AstraZeneca Colorectal cancer Phase 2 study of CV301 plus OPDIVO (nivolumab) in micro satellite stable mcrc (n=74) Physician sponsored (Rutgers University) study with drug supply commitment from BMS 6
7 BRACHYURY PHASE 1: DATA IN H An Open-label Phase 1 Trial to Evaluate the Safety and Tolerability of a Modified Vaccinia Ankara (MVA) Priming Followed by Fowlpox Booster Vaccines Modified to Express Brachyury and T-cell Costimulatory Molecules: Initiated in January 2018 Status: 4 patients enrolled (2 pts with chordoma on study) 3 patients currently in screening Enrollment anticipated full by June. Topline data anticipated in H Safety and initial immune response data Data presentation anticipated at scientific congress A previous Phase 1 study of 38 patients receiving only MVA-BN Brachyury showed presence of brachyury specific T cells in vast majority of patients, post-treatment* 7
8 BRACHYURY: QUICK EFFICACY SEEKING TRIAL (QUEST STUDY) A sequential cohort study of combination immunotherapy with BNbrachyury vaccine, M7824, ALT-803 and epacadostat in metastatic castrationresistant prostate cancer (mcrpc). NCI sponsored trial exploring multiple combinations of immunotherapy with BN-Brachyury as backbone therapy NCI collaboration between 4 companies M7824: EMD Serono, anti PD- L1/ anti-tgf-β ALT-803: Altor Biosciences, IL- 15 superagonist Epacadostat: Incyte, IDO inhibitor 8 ClinicalTrials.gov Identifier: NCT
9 BN-BRACHYURY: CHORDOMA POTENTIAL REGISTRATION PATHWAY IN ULTRA ORPHAN CANCER: CHORDOMA Phase 2 planned to initiate Q Combination with radiation in advanced metastatic chordoma Primary endpoint: Objective response rate (radiation alone <5% ORR at 6 months) Recently granted Orphan Drug Designation Potential for Breakthrough Designation Population Patients with advanced, incurable chordoma At least 1 measurable lesion eligible for radiation therapy Stage 1 12 patients Only proceed to stage 2 if at least 2 objective responses occur Stage 2 Enroll additional 13 patients. ORR goal = 20% (5/25 patients) 9
10 CD8 C e l l c o u n t p e r C a n c e r C e l l C D 4 / T u m o r c e l l s ASCO: KEY TAKEAWAYS Early stage patients show an upregulation of cancer specific T cells Effect of PROSTVAC on intra/peritumoral immune infiltrate in patients with localized prostate cancer undergoing radical prostatectomy. 2X increase in PSA specific TILs in vast majority of patients (See below) Safety seen when combining PROSTVAC and nivolumab Combination established as safe and well tolerated NCI will now move to treating men with neoadjuvant Prostate Cancer. (n=17) This will allow investigators the opportunity to see if there is synergy in combining vaccine and checkpoint inhibition, for men with early stage disease. P a i r e d t t e s t d a t a P a i r e d t t e s t d a t a C o n t r o l T r e a t m e n t C o n t r o l T r e a t e d
11 AT THE FOREFRONT OF RSV VACCINE DEVELOPMENT Novel Vaccine Design Encodes 5 distinct targets of RSV to stimulate a broad protective immune response (T-cell and antibody response) mimicking a natural infection of RSV F (A) G (A) G (B) N M2 Competitive Advantages Induction of a broad T-cell and antibody response against RSV Induction of mucosal immunity Durable immune response lasting an RSV season Based on MVA-BN live virus adjuvant with a favorable safety profile Clinical Development Plan Ongoing booster study Human challenge trial Phase 3 initiation
12 PHASE 2 BOOSTER STUDY: DATA MID 2018 Key objectives of booster study Get clarity on long-term durability of immune response (12 months) Evaluate effect of a single booster dose after primary vaccination with a single shot using same doses as in the main study (N=86) Adult population 55 years of age; N=80 per group IM administration of vaccine or placebo on Day 0 and Day 28 Randomization 1 x 10 8 Day 0 Placebo Day 28 1 x 10 8 Day 0 1 x 10 8 Day 28 5 x 10 8 Day 0 Placebo Day 28 5 x 10 8 Day 0 5 x 10 8 Day 28 Placebo Day 0 Placebo Day 28 Booster 1 x 10 8 Booster 5 x 10 8 N=43 N=43 12
13 OUR COLLABORATION WITH JANSSEN A LONG-TERM VALUE DRIVER 4 license agreements in place The combination of Janssen s AdVac + MVA-BN has demonstrated robust and sustained immune responses in people The synergistic benefit of combining our technology has been key to establishing collaborations in blockbuster indications Equity investments have made JNJ a major shareholder with ownership of 5.77% MVA-BN Filo (Ebola) Phase 3 ongoing MVA-BN HPV MVA-BN HIV Phase 1 in 2018 Phase 1 in 2018 Potential milestone payments of ~$1BN + royalties MVA-BN HBV 13
14 FREEZE-DRIED IMVAMUNE CONTRACT WITH USG TIMELINES AND REVENUES onwards $233M bulk $100M bulk $140M clinical / regulatory support $299M Potential additional IMVAMUNE orders 14 Bulk vaccine Construction of fill/finish plant Freeze-dried IMVAMUNE
15 FINANCIAL RESULTS AND OUTLOOK Financially on target with modest revenues during Q1 as most revenues from IMVAMUNE bulk vaccine will occur in H2 A total of 350 mdkk will be invoiced for IMVAMUNE in 2018, including RoW contracts Other revenue of 150 mdkk relates to already signed R&D contracts Q mdkk FY2018E Revenue EBIT (173) (385) Cash preparedness 2,355* 1,850 Cash preparedness includes cash, cash equivalents, investments in securities and the aggregate amount of undrawn credit lines. * DKK 110 million deducted by loans related to repo transactions musd Q FY (29) (64) USD/DKK =
16 WE ARE WELL FUNDED A large cash flow from secured contracts and potential milestones in the coming years Freedom to execute on strategy DKK million USD million Cash preparedness 2, IMVAMUNE contracts with USG, signed 3, Other ongoing contracts Priority Review Voucher, sale Janssen partnership, potential milestone payments 6,000 1,000 Total DKK 12.5 billion ~$2.1billion USD/DKK:
17 PIPELINE AMBITIOUS AND WELL-BALANCED PORTFOLIO Infectious diseases Oncology PRODUCT INDICATION PHASE 1 PHASE 2 PHASE 3 PARTNER IMVAMUNE liquid-frozen 1) Smallpox File H IMVAMUNE freeze-dried MVA-BN RSV CV301 + pembrolizumab Smallpox RSV Lung cancer (NSCLC) CV301 + atezolizumab Bladder cancer Planned 2018 CV301 + durvalumab Colorectal cancer Planned 2018 CV301 + nivolumab Colorectal cancer Planned 2018 BN-Brachyury Chordoma Planned 2018 PROSTVAC combinations MVA-BN Filo + AdVac MVA-BN Filo + AdVac Prostate cancer Ebola Ebola/Marburg MVA-BN HPV + AdVac Chronic HPV infection Planned 2018 MVA-BN HIV + AdVac HIV1 Infected Planned 2018 MVA-BN HBV + AdVac Hepatitis B infected 1) Approved in Canada and the European Union (marketed as IMVANEX in the EU). Phase 3 completed in the U.S. 17
18 ANTICIPATED SELECTED MILESTONES IMVAMUNE Filing of BLA for liquid-frozen IMVAMUNE (H2, 2018) Anticipated BLA approval and award of a Priority Review Voucher (2019) Initiation of a Phase 3 IMVAMUNE freeze-dried lot consistency study (2019) RSV Results from booster-study (H1, 2018) Decide on the feasibility of a human challenge study (H2, 2018) JANSSEN Initiate Phase 1 study of MVA-BN HIV+AdVac (H2, 2018*) Initiate Phase 1 study of MVA-BN HPV+AdVac (H2, 2018*) CV301 Initiate Phase 2 study in combination with atezolizumab in bladder cancer (mid 2018) Initiate Phase 2 study in combination with durvalumab in colorectal cancer (H1, 2018) Initiate Phase 2 study in combination with nivolumab in colorectal cancer (H1, 2018) Initial Phase 2 results (ORR) from combination with pembrolizumab in NSCLC (H2, 2018) BRACHYURY Results from Phase 1 booster study (H2, 2018) Initiate Phase 2 study in Chordoma (H2, 2018) * Janssen is responsible for the clinical development 18
19 19
20
JEFFERIES 2018 LONDON HEALTHCARE CONFERENCE NOVEMBER 15, 2018
1 JEFFERIES 2018 LONDON HEALTHCARE CONFERENCE NOVEMBER 15, 2018 FORWARD-LOOKING STATEMENTS This presentation includes forward-looking statements that involve risks, uncertainties and other factors, many
More informationINTERIM RESULTS AS OF JUNE 30, 2017
INTERIM RESULTS AS OF JUNE 30, 2017 1 FORWARD-LOOKING STATEMENTS This presentation includes forward-looking statements that involve risks, uncertainties and other factors, many of which are outside of
More informationINTERIM RESULTS AS OF JUNE 30, 2016 CSE/OMX:BAVA, OTC:BVNRY
INTERIM RESULTS AS OF JUNE 30, 2016 Q2 CSE/OMX:BAVA, OTC:BVNRY FORWARD-LOOKING STATEMENTS This presentation includes forward-looking statements that involve risks, uncertainties and other factors, many
More informationFORWARD-LOOKING STATEMENTS
NOVEMBER 2017 1 FORWARD-LOOKING STATEMENTS This presentation includes forward-looking statements that involve risks, uncertainties and other factors, many of which are outside of our control that could
More informationFORWARD-LOOKING STATEMENTS
DECEMBER 2017 1 FORWARD-LOOKING STATEMENTS This presentation includes forward-looking statements that involve risks, uncertainties and other factors, many of which are outside of our control that could
More informationTHE FUTURE OF VACCINES ASCO ANNUAL MEETING JUNE 4, 2016
THE FUTURE OF VACCINES ASCO ANNUAL MEETING JUNE 4, 2016 1 BAVARIAN NORDIC INVESTOR & ANALYST UPDATE & RECEPTION Welcome and Introduction to Bavarian Nordic s Cancer immunotherapy Programs Paul Chaplin,
More informationINTERIM RESULTS AS OF JUNE 30, 2014 CSE/OMX:BAVA, OTC:BVNRY
INTERIM RESULTS AS OF JUNE 30, 2014 Q2 AUGUST 28, 2014 CSE/OMX:BAVA, OTC:BVNRY FINANCIAL HIGHLIGHTS 2.6 million doses IMVAMUNE delivered to the SNS during H1 (0.9 million in Q2) Increased contribution
More informationFORWARD-LOOKING STATEMENTS
NOVEMBER 2017 1 FORWARD-LOOKING STATEMENTS This presentation includes forward-looking statements that involve risks, uncertainties and other factors, many of which are outside of our control that could
More informationINTERIM RESULTS AS OF MARCH 31, 2014 CSE/OMX:BAVA, OTC:BVNRY
INTERIM RESULTS AS OF MARCH 31, 2014 Q1 MAY 14, 2014 CSE/OMX:BAVA, OTC:BVNRY FINANCIAL HIGHLIGHTS 1.7 million doses delivered to the SNS during Q1 Full year financial expectations maintained DKK million
More informationTHE FUTURE OF VACCINES DECEMBER 2016
THE FUTURE OF VACCINES DECEMBER 2016 1 FORWARD-LOOKING STATEMENTS This presentation includes forward-looking statements that involve risks, uncertainties and other factors, many of which are outside of
More informationCITI EUROPEAN HEALTHCARE CONFERENCE JUNE 2017
CITI EUROPEAN HEALTHCARE CONFERENCE 2017 20 JUNE 2017 1 FORWARD-LOOKING STATEMENTS This presentation includes forward-looking statements that involve risks, uncertainties and other factors, many of which
More informationBAVARIAN NORDIC BIO DEUTSCHLAND PRESENTATION OCTOBER 2014 CSE/OMX:BAVA, OTC:BVNRY
BAVARIAN NORDIC BIO DEUTSCHLAND PRESENTATION OCTOBER 2014 CSE/OMX:BAVA, OTC:BVNRY This presentation includes "forward-looking statements" that involve risks, uncertainties and other factors, many of which
More informationJefferies 2016 Healthcare Conference. Reid Huber, PhD Chief Scientific Officer
Jefferies 2016 Healthcare Conference Reid Huber, PhD Chief Scientific Officer June 8, 2016 Forward-looking Statements Except for the historical information set forth herein, the matters set forth in this
More informationDynavax Corporate Presentation
Dynavax Corporate Presentation Forward-Looking Statements This presentation contains forward-looking statements, including statements regarding our HEPLISAV-B TM regulatory submissions, product profile,
More informationCorporate Presentation October 2018 Nasdaq: ADXS
Innovations in Immuno-Oncology Corporate Presentation October 2018 Nasdaq: ADXS Forward-Looking Statements This presentation contains forward-looking statements, including, but not limited to, statements
More informationADAPTIMMUNE INVESTOR PRESENTATION. August 2016
ADAPTIMMUNE INVESTOR PRESENTATION August 2016 DISCLAIMER This presentation contains forward-looking statements, as that term is defined under the Private Securities Litigation Reform Act of 1995 (PSLRA),
More informationRecurrent Ovarian Cancer Phase 1b Results
Recurrent Ovarian Cancer Phase 1b Results December 5 th, 2017 Forward-looking Statements Except for historical information, this presentation contains forward-looking statements, which reflect Immunovaccine
More informationBank of America Merrill Lynch 2016 Health Care Conference
Bank of America Merrill Lynch 2016 Health Care Conference Dr. Steven Stein Chief Medical Officer David Gryska Chief Financial Officer May 11, 2016 Forward Looking Statements Except for the historical information
More informationCorporate Presentation September Nasdaq: ADXS
Corporate Presentation September 2018 Nasdaq: ADXS Forward-Looking Statements This presentation contains forward-looking statements, including, but not limited to, statements regarding the ability and
More informationCombining HS-110 and anti-pd-1 in NSCLC. September 1, 2015
Combining HS-110 and anti-pd-1 in NSCLC September 1, 2015 Forward Looking Statements This presentation includes statements that are, or may be deemed, forward-looking statements. In some cases, these forward-looking
More informationPositioned for Growth
Positioned for Growth Annual Shareholders Meeting July 21, 2016 Paris Panayiotopoulos President and Chief Executive Officer David Sachs Non small cell lung cancer ARIAD clinical trial patient This presentation
More informationNational Bank 8th Annual Quebec Conference TSX: IMV. May 30, IMV Inc. All rights reserved.
National Bank 8th Annual Quebec Conference TSX: IMV May 30, 2018 Forward-looking Statements Except for historical information, this presentation contains forward-looking statements, which reflect IMV Inc.
More information33 rd Annual J.P. Morgan Healthcare Conference. January 2015
33 rd Annual J.P. Morgan Healthcare Conference January 2015 Forward-looking Statements This presentation contains forward-looking statements, which express the current beliefs and expectations of management.
More informationDetermined to realize a future in which people with cancer live longer and better than ever before Q Conference Call
Reimagining Cancer Treatment Determined to realize a future in which people with cancer live longer and better than ever before Q1 2016 Conference Call 1 Forward-Looking Statements Disclosure This presentation
More informationJune IMMUNE DESIGN The in vivo generation of cytotoxic CD8 T cells (CTLs)
June 2015 IMMUNE DESIGN The in vivo generation of cytotoxic CD8 T cells (CTLs) 1 Forward-looking Statements This presentation contains forward-looking statements with respect to, among other things, our
More informationNewLink Genetics Corporation Provides Operational Update and Reports Second Quarter 2015 Financial Results
July 31, 2015 NewLink Genetics Corporation Provides Operational Update and Reports Second Quarter 2015 Financial Results -Management to Host Conference Call Today at 8:30 a.m. ET- AMES, Iowa, July 31,
More informationDawson James Conference
Dawson James Conference October 2018 Forward-looking Statements Except for historical information, this presentation contains forward-looking statements, which reflect IMV s current expectations regarding
More informationHALOZYME REPORTS SECOND QUARTER 2018 RESULTS
Contacts: Robert H. Uhl Managing Director Westwicke Partners, LLC 858-356-5932 robert.uhl@westwicke.com Laurie Stelzer 858-704-8222 ir@halozyme.com FOR IMMEDIATE RELEASE HALOZYME REPORTS SECOND QUARTER
More informationNewLink Genetics Corporation
Cantor Fitzgerald Global Healthcare Conference NewLink Genetics Corporation NASDAQ: NLNK September 25, 2017 Forward-Looking Disclaimer This presentation contains forward-looking statements of NewLink that
More informationLION. Corporate Presentation June 2016 BIOTECHNOLOGIES. Leadership & Innovation in Oncology
LION BIOTECHNOLOGIES Leadership & Innovation in Oncology Corporate Presentation June 2016 Forward-Looking Statements This presentation contains forward-looking statements within the meaning of the Private
More informationBuilding a Premier Oncology Biotech
Corporate Deck Building a Premier Oncology Biotech Dr. Helen Torley, President and CEO November 2018 Forward-Looking Statements All of the statements in this presentation that are not statements of historical
More informationTHE FUTURE OF VACCINES JANUARY 2016
THE FUTURE OF VACCINES JANUARY 2016 1 This presentation contains forward-looking statements. All statements other than statements of historical facts contained in this presentation constitute forward-looking
More informationFOURTH QUARTER AND FULL YEAR 2018 FINANCIAL RESULTS AND BUSINESS UPDATE. Thursday, February 7, 2019
FOURTH QUARTER AND FULL YEAR 2018 FINANCIAL RESULTS AND BUSINESS UPDATE Thursday, February 7, 2019 Today s Speakers Overview and Key Highlights Clay Siegall, President & CEO Financial Results and Guidance
More informationNektar Investor & Analyst Call. Nektar & z Bristol-Myers Squibb Collaboration. February 14, 2018
Nektar Investor & Analyst Call Nektar & z Bristol-Myers Squibb Collaboration February 14, 2018 This presentation includes forward-looking statements regarding Nektar s proprietary drug candidates, the
More informationMagazine CELEBRATIONS CEO and President Anders Hedegaard looks back on a year with several landmark events for the company.
A YEAR OF CELEBRATIONS CEO and President Anders Hedegaard looks back on a year with several landmark events for the company. PAGE04 Magazine 2013 Bavarian Nordic IMVAMUNE FIRST 20 MILLION DOSES NOW DELIVERED
More informationPSMA-617 License Transaction. October 2, 2017
PSMA-617 License Transaction October 2, 2017 Forward Looking Statements Certain of the statements made in this presentation are forward looking, such as those, among others, relating to future spending,
More informationThird Quarter 2015 Earnings Call. November 9, 2015
Third Quarter 2015 Earnings Call November 9, 2015 Forward-Looking Statements All of the statements in this presentation that are not statements of historical facts constitute forward-looking statements
More informationWells Fargo Healthcare Conference September 6, 2018
Wells Fargo Healthcare Conference September 6, 2018 Safe Harbor Statement To the extent that statements contained in this presentation are not descriptions of historical facts regarding TESARO, they are
More informationAcquisition of Novartis Influenza Vaccines Business. 27 th October 2014
1 Acquisition of Novartis Influenza Vaccines Business 27 th October 2014 2 Legal Notice Forward looking statements The materials in this presentation speak only as of the date of these materials, and include
More informationOncoSec Provides 2018 Business Outlook
January 3, 2018 OncoSec Provides 2018 Business Outlook Complete stage 1 enrollment of PISCES/KEYNOTE-695 clinical trial of ImmunoPulse IL-12 in combination with KEYTRUDA (pembrolizumab) Present preliminary
More informationOncology Therapeutics without Compromise APRIL 2011
Oncology Therapeutics without Compromise APRIL 2011 Forward Looking Statements This presentation contains forward-looking statements that involve substantial risks and uncertainties, including among other
More informationBuilding a Premier Oncology Biotech
Building a Premier Oncology Biotech August 208 Forward-Looking Statements All of the statements in this presentation that are not statements of historical facts constitute forward-looking statements within
More informationCOMPANY OVERVIEW. June CytomX Therapeutics, Inc.
COMPANY OVERVIEW June 2016 2016 CytomX Therapeutics, Inc. Forward Looking Statements Special Note Regarding Forward-Looking Statements This presentation may contain projections and other forward-looking
More informationAt the forefront of cancer immunotherapy. Investor Presentation January 2018
1 At the forefront of cancer immunotherapy Investor Presentation January 2018 Disclaimer Certain statements made in this presentation are forward looking statements within the meaning of the safe harbour
More informationTargeting and Treating Cancer
Targeting and Treating Cancer Mark R. Baker, Chief Executive Officer Jefferies 2016 DISCLOSURE NOTICE This presentation may contain projections and other forward-looking statements regarding future events.
More informationDS-8201 Strategic Collaboration
DS-8201 Strategic Collaboration DAIICHI SANKYO CO., LTD George Nakayama Chairman and CEO March 29, 2019 Forward-Looking Statements Management strategies and plans, financial forecasts, future projections
More informationFirst Phase 3 Results Presented for a PD-1 Immune Checkpoint Inhibitor
September 30, 2014 Positive Phase 3 Data for Opdivo (nivolumab) in Advanced Melanoma Patients Previously Treated with Yervoy @ (ipilimumab) Presented at the ESMO 2014 Congress First Phase 3 Results Presented
More informationMerck ASCO 2015 Investor Briefing
Merck ASCO 2015 Investor Briefing Forward-Looking Statement This presentation includes forward-looking statements within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation
More informationBuilding a Premier Oncology Biotech
Wells Fargo Securities Healthcare Conference Building a Premier Oncology Biotech Dr. Helen Torley, President and CEO September 2018 Forward-Looking Statements All of the statements in this presentation
More informationDetermined to realize a future in which people with cancer live longer and better than ever before
Determined to realize a future in which people with cancer live longer and better than ever before 3Q 2018 EARNINGS PRESENTATION NOVEMBER 2018 1 Forward-looking statements disclosure This presentation
More informationClinical: Ipilimumab (MDX-010) Update and Next Steps
Clinical: Ipilimumab (MDX-010) Update and Next Steps Geoffrey M. Nichol, M.D., M.B.A. Senior Vice President, Product Development Medarex, Inc. R&D Day December 9, 2005 Ipilimumab: New Class of Cancer Therapy
More informationForward-Looking Statements
Investor Presentation May 2012 Forward-Looking Statements Statements contained herein that are not historical facts are forward-looking statements within the meaning of the Securities Act of 1933, as amended.
More informationInvestor Webcast: Initial Data from Phase 1a/1b Trial of Cabiralizumab/OPDIVO and Early Efficacy Signal in Pancreatic Cancer.
Investor Webcast: Initial Data from Phase 1a/1b Trial of Cabiralizumab/OPDIVO and Early Efficacy Signal in Pancreatic Cancer November 8, 2017 NASDAQ:FPRX Forward-Looking Statements Disclaimer This presentation
More informationLEVERAGING FDA S ACCELERATED PATHWAYS FOR MARKET ADVANTAGE
WHITE PAPER LEVERAGING FDA S ACCELERATED PATHWAYS FOR MARKET ADVANTAGE Over the past 15 years, the FDA and Congress developed several accelerated pathways to provide incentives for manufacturers to develop
More informationInovio Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter)
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event
More informationClovis Oncology Announces Q Operating Results and Corporate Update. November 3, :05 PM ET
Clovis Oncology Announces Q3 2016 Operating Results and Corporate Update November 3, 2016 4:05 PM ET Rucaparib New Drug Application (NDA) accepted for Priority Review in the treatment of advanced BRCA-mutant
More informationSunesis Pharmaceuticals Reports Second Quarter 2011 Financial Results
Investor and Media Inquiries: David Pitts Argot Partners 212-600-1902 Eric Bjerkholt Sunesis Pharmaceuticals Inc. 650-266-3717 Sunesis Pharmaceuticals Reports Second Quarter 2011 Financial Results SOUTH
More informationIMMUNOMEDICS, INC. Advanced Antibody-Based Therapeutics. Jefferies 2014 Global Healthcare Conference Cynthia L. Sullivan, President and CEO
IMMUNOMEDICS, INC. Advanced Antibody-Based Therapeutics Oncology Autoimmune Diseases Jefferies 2014 Global Healthcare Conference Cynthia L. Sullivan, President and CEO Forward-Looking Statements This presentation,
More informationCORPORATE PRESENTATION
CORPORATE PRESENTATION June 2017 FORWARD LOOKING SAFE HARBOR STATEMENT This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.
More informationDetermined to realize a future in which people with cancer live longer and better than ever before
Determined to realize a future in which people with cancer live longer and better than ever before 4Q 2016 EARNINGS PRESENTATION MARCH 2017 1 Forward-looking statements disclosure This presentation contains
More informationArming the patient s immune system to fight cancer
Arming the patient s immune system to fight cancer Redeye - Fight Cancer Seminar 10 th March 2017 Øystein Soug, CEO Important notice and disclaimer This report contains certain forward-looking statements
More informationCorporate Presentation
Corporate Presentation Leerink Global Healthcare Conference February 14 th -15 th, 2018 C O N F I D E N T I A L a n d P R O P R I E T A R Y Forward Looking Statements / Safe Harbor This presentation contains
More informationCancer Immunotherapy Survey
CHAPTER 8: Cancer Immunotherapy Survey All (N=100) Please classify your organization. Academic lab or center Small biopharmaceutical company Top 20 Pharma Mid-size pharma Diagnostics company Other (please
More information9M RESULTS 2014 CONFERENCE CALL DR. MATTHIAS SCHROFF, CEO
9M RESULTS 2014 CONFERENCE CALL DR. MATTHIAS SCHROFF, CEO BERLIN, 13 NOVEMBER, 2014 Disclaimer Certain statements in this presentation contain formulations or terms referring to the future or future developments,
More informationClovis Oncology Announces First Quarter 2017 Operating Results. May 3, :06 PM ET
Clovis Oncology Announces First Quarter 2017 Operating Results May 3, 2017 4:06 PM ET Strong Q1 launch quarter for Rubraca (rucaparib) in U.S. with $7M reported in net sales Clovis notified that ARIEL3
More informationBusiness Update & Financial Results for Q1 2018
Business Update & Financial Results for Q1 2018 May 15, 2018 Disclaimer The statements made in this presentation may include forward-looking statements regarding the future operations of ERYTECH Pharma
More informationTELECONFERENCE FY February 2015
TELECONFERENCE FY 2014 5 February 2015 Company disclaimer This presentation contains forward-looking statements that provide our expectations or forecasts of future events such as new product introductions,
More informationInvestor Presentation June 2012 NASDAQ: CEMI
Investor Presentation June 2012 NASDAQ: CEMI Forward-Looking Statements Statements contained herein that are not historical facts are forward-looking statements within the meaning of the Securities Act
More informationMOLOGEN AG. Our research for you. Annual Results Analysts Call March 21, 2013
Our research for you. Annual Results 2012 Analysts Call March 21, 2013 Disclaimer Certain statements in this communication contain formulations or terms referring to the future or future developments,
More informationHALOZYME THERAPEUTICS, INC. (Exact name of registrant as specified in its charter)
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event
More informationTransgene Reviews Product Pipeline, Provides a Business Update and Outlines its Corporate Strategy
Transgene Reviews Product Pipeline, Provides a Business Update and Outlines its Corporate Strategy Parc d Innovation, Illkirch, France, March 22, 2010 Transgene (Euronext Paris: FR0005175080) details its
More informationTargeting and Treating Cancer
Targeting and Treating Cancer Mark R. Baker CEO Jefferies Healthcare Conference June 8, 2017 DISCLOSURE NOTICE This presentation may contain projections and other forward-looking statements regarding future
More informationIntercell and Novartis form world leading strategic partnership to drive vaccines innovation
Intercell and Novartis form world leading strategic partnership to drive vaccines innovation Alliance creates opportunity for two strong innovators to combine development efforts in attractive areas Intercell
More informationDeveloping & Commercializing Targeted Small Molecule Drugs in Cancer
Developing & Commercializing Targeted Small Molecule Drugs in Cancer SAFE HARBOR STATEMENT 2 Forward-looking statements made in the course of this presentation are made pursuant to the safe harbor provisions
More informationPLENARY SESSION 1: CLINICAL TRIAL DESIGN IN AN ERA OF HORIZONTAL DRUG DEVELOPMENT Industry Perspective
PLENARY SESSION 1: CLINICAL TRIAL DESIGN IN AN ERA OF HORIZONTAL DRUG DEVELOPMENT Industry Perspective Davy Chiodin, VP - Regulatory Science, QA and Compliance, Acerta Pharma (A Member of the AstraZeneca
More informationAt the forefront of cancer immunotherapy. Investor Presentation January 2018
1 At the forefront of cancer immunotherapy Investor Presentation January 2018 Investment highlights Lead investigational product CAVATAK kills cancer cells with a bio-selected form of the common cold virus
More informationAviragen Therapeutics, Inc. and Vaxart Inc. Joint Conference Call UNLOCKING THE FULL POTENTIAL OF ORAL VACCINES
Aviragen Therapeutics, Inc. and Vaxart Inc. Joint Conference Call UNLOCKING THE FULL POTENTIAL OF ORAL VACCINES October 30, 2017 Safe Harbor This presentation contains forward-looking statements about
More informationInvestor Presentation
Investor Presentation February 2018 2 FORWARD-LOOKING INFORMATION The following presentation contains statements that are considered forward-looking information ( FLI ) within the meaning of securities
More informationIncyte Corporation. Q Financial and Corporate Update August 9, 2016
Incyte Corporation Q2 2016 Financial and Corporate Update August 9, 2016 Speakers Hervé Hoppenot Chief Executive Officer David Gryska Chief Financial Officer Barry Flannelly General Manager, U.S. Reid
More informationAsterias Biotherapeutics NYSE American: AST
Clinical-Stage Cell Therapy Programs Addressing Significant Unmet Medical Needs in Neurology and Oncology Asterias Biotherapeutics NYSE American: AST November 2017 Forward-Looking Statements Statements
More informationMERCK ONCOLOGY OVERVIEW ASCO 2018 JUNE 4, 2018
MERCK ONCOLOGY OVERVIEW ASCO 218 JUNE 4, 218 Forward-Looking Statement of Merck & Co., Inc., Kenilworth, NJ, USA This presentation of Merck & Co., Inc., Kenilworth, N.J., USA (the company ) includes forward
More informationTargeting and Treating Cancer
Targeting and Treating Cancer Mark R. Baker, Chief Executive Officer Jefferies Healthcare Conference June 2015 Disclosure Notice This presentation may contain projections and other forward-looking statements
More informationA world leader in allergy immunotherapy
A world leader in allergy immunotherapy Investor Relations presentation June 2017 1 I Investor Relations presentation I June 2017 ALK: Towards redefining treatment of severe allergies The commercial leader
More informationIdenix Pharmaceuticals Building a Leading Antiviral Franchise. Cowen & Company 27 th Annual Healthcare Conference March 13, 2007 Boston
Idenix Pharmaceuticals Building a Leading Antiviral Franchise Cowen & Company 27 th Annual Healthcare Conference March 13, 2007 Boston Safe Harbor This presentation includes forward-looking statements
More informationIncyte Reports 2014 Second Quarter Financial Results and Updates Shareholders on Key Clinical Programs
Print Page Close Window Press Release Incyte Reports 2014 Second Quarter Financial Results and Updates Shareholders on Key Clinical Programs $84.0 million of 2014 second quarter net product revenues from
More informationThe Galectin-3 Inhibitor GR-MD-02 for Combination Cancer Immunotherapy
The Galectin-3 Inhibitor GR-MD-02 for Combination Cancer Immunotherapy Supplemental Information to Corporate Presentation February 6, 2018 NASDAQ: GALT www.galectintherapeutics.com 2018 2017 Galectin Therapeutics
More information3Q 2016 presentation
Arming the patient s immune system to fight cancer 3Q 2016 presentation 17 November 2016 Important notice and disclaimer This report contains certain forward-looking statements based on uncertainty, since
More informationAnalyst/Investor Call
Analyst/Investor Call November 20 th, 2018 Forward-looking Statements Except for historical information, this presentation contains forward-looking statements, which reflect IMV s current expectations
More informationMore cancer patients are being treated with immunotherapy, but
Bristol-Myers Squibb and Five Prime Present Phase 1a/1b Data Evaluating Cabiralizumab (anti-csf-1 receptor antibody) with Opdivo (nivolumab) in Patients with Advanced Solid Tumors PRINCETON, N.J. & SOUTH
More informationIncyte Corporation. J.P. Morgan Healthcare Conference January 9, 2017
Incyte Corporation J.P. Morgan Healthcare Conference January 9, 2017 Forward-looking Statements Except for the historical information set forth herein, the matters set forth in this presentation contain
More informationImmune Checkpoint Inhibitors: The New Breakout Stars in Cancer Treatment
Immune Checkpoint Inhibitors: The New Breakout Stars in Cancer Treatment 1 Introductions Peter Langecker, MD, PhD Executive Medical Director, Global Oncology Clinipace Worldwide Mark Shapiro Vice President
More informationNASDAQ & TSX: IMV. BIO Investor Forum. October IMV Inc. All rights reserved.
NASDAQ & TSX: IMV BIO Investor Forum October 2018 Forward-looking Statements Except for historical information, this presentation contains forward-looking statements, which reflect IMV s current expectations
More informationBuilding a Premier Oncology Biotech
Corporate Presentation Building a Premier Oncology Biotech Dr. Helen Torley, President and CEO February 2019 Forward-Looking Statements All of the statements in this presentation that are not statements
More informationJuly, ArQule, Inc.
July, 2012 Safe Harbor This presentation and other statements by ArQule may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act with respect to clinical
More informationMOLOGEN AG. Pioneering Immune Therapy. Q1 Results 2014 Conference Call. Dr. Matthias Schroff, CEO
Pioneering Immune Therapy Q1 Results 2014 Conference Call Dr. Matthias Schroff, CEO Berlin, 14 May 2014 V1-6 Disclaimer Certain statements in this presentation contain formulations or terms referring to
More informationBuilding a Premier Oncology Biotech
Corporate Presentation Building a Premier Oncology Biotech Dr. Helen Torley, President and CEO January 2019 Forward-Looking Statements All of the statements in this presentation that are not statements
More informationVAL-083: Validated DNA-targeting Agent for Underserved Cancer Patients. September 2018
VAL-083: Validated DNA-targeting Agent for Underserved Cancer Patients September 2018 Forward-Looking Statements Any statements contained in this presentation that do not describe historical facts may
More informationAnti-IL-33 (ANB020) Program
Anti-IL-33 (ANB020) Program Phase 2a Peanut Allergy Clinical Trial Interim Data Update March 26 th 2018 NASDAQ: ANAB Safe Harbor Statement This presentation and the accompanying oral presentation contain
More informationNOVEL CHECKPOINTS IN IMMUNO-ONCOLOGY KIR NKG2A. C5aR. NKp46 HALF-YEAR RESULTS. Tumor antigen KIR3DL2 CD39 MICA/B CD73 SEPTEMBER 18, 2017
NOVEL CHECKPOINTS IN IMMUNO-ONCOLOGY KIR NKG2A NKp46 C5aR Tumor antigen HALF-YEAR RESULTS KIR3DL2 MICA/B CD73 CD39 SEPTEMBER 18, 2017 Page 2 FORWARD LOOKING STATEMENT This document has been prepared by
More information